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ABSTRACT 
 
Background: Evidence suggests that gestational diabetes mellitus (GDM) is associated with var-
ious metabolic conditions including elevated cholesterol, low HDL, elevated LDL, elevated tri-
glycerides and obesity. However, comparative data on the association between GDM and various 
metabolic conditions across racial/ethnic groups are rare. This study focuses on differences in 
metabolic profiles among pregnant Non-Hispanic (NH) Whites, NH-Blacks, Mexican-Americans 
and women of other races/ethnicities with prediabetes and diabetes. 
 
Method: Available data from the 1999 to 2010 survey waves of the National Health and Nutri-
tion Examination Survey (NHANES) was used for this study. NHANES uses a stratified multi-
stage probability sample of the civilian non-institutionalized population of the US chosen from a 
broad range of age groups and racial/ethnic backgrounds. Descriptive statistics were used to de-
scribe demographic variables, metabolic profiles across prediabetes/diabetes status. Univariate 
and multivariate logistic regression analyses were then used to determine the association between 
metabolic variables and prediabetes/diabetes across race/ethnicity. 
 
Results: The study population (n=1417) consisted NH-Whites (N=620), NH-Blacks (N=219), 
Mexican-Americans (N=420), and “Other” races (N=168). Individuals with high LDL levels 
were significantly more likely to be diagnosed with GDM when compared to those with low 
LDL in both the crude (OR= 3.47, 95% CI= 1.90-6.33) and adjusted (OR= 2.81, 95% CI= 1.17-
6.75) models. Individuals with high triglycerides levels were significantly more likely to be di-
agnosed with GDM when compared with individuals with low triglycerides in both the crude 
(OR= 2.44,95% CI= 1.36-4.38), and adjusted (OR= 1.30, 95% CI= 0.56-3.01) models. Individu-
als who are overweight/obese were significantly more likely to be diagnosed with GDM when 
compared with individuals normal weight both the crude (OR= 3.13, 95% CI= 1.28-7.64), and 
adjusted (OR= 2.44, 95% CI= 1.02-5.86) models. NH-Whites with elevated LDL and increased 
BMI are significantly more likely to be diagnosed with GDM; NH-Blacks with elevated triglyc-
erides and increased BMI are significantly more likely to be diagnosed with GDM; Mexican-
Americans with elevated triglycerides and increased BMI were significantly more likely to be 
diagnosed with GDM; Individuals of “Other” races with elevated LDL were significantly more 
likely to be diagnosed with GDM 
 
Conclusion:  With the exception of non-Hispanic Whites, pregnant American women with high-
er levels of cholesterols, high triglycerides, increased body mass index (25 kg/m2 or greater), and 
less than high school education were found to be at greater risks of diabetes. The result of this 
analysis suggests that healthcare professionals should be more aggressive in controlling these 
metabolic abnormalities in pregnant women. Early intervention prior to pregnancy may help de-
lay the onset of prediabetes/diabetes. Empowerment of pregnant women in the management of 
their diabetes may also be critical in averting the detrimental effect of these metabolic abnormali-
ties. 
 
 
 
iii 
 
 
APPROVAL PAGE 
 
Racial/Ethnic Differences in Metabolic Profiles of  
American Women With Diagnosed Diabetes Mellitus 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Approved:  
___________Dr. Ike Okosun___________________  
Committee Chair  
___________Dr. Kim Ramsey-White____________ 
Committee Member  
  
Date: December 17, 2013 
 
iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Nta Ekeng Henshaw, MD 
2013  
vi 
 
vi 
 
DEDICATION 
This thesis is dedicated to God and to my family. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ii 
 
Author’s Statement Page 
 
In presenting this thesis as a partial fulfillment of the requirements for an ad-
vanced degree from Georgia State University, I agree that the Library of the University 
shall make it available for inspection and circulation in accordance with its regulations 
governing materials of this type. I agree that permission to quote from, to copy from, or 
to publish this thesis may be granted by the author or, in his/her absence, by the professor 
under whose direction it was written, or in his/her absence, by the Associate Dean, Col-
lege of Health and Human Sciences. Such quoting, copying, or publishing must be solely 
for scholarly purposes and will not involve potential financial gain. It is understood that 
any copying from or publication of this dissertation which involves potential financial 
gain will not be allowed without written permission of the author.  
 
_______Nta E. Henshaw__________  
Signature of Author  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
 
Notice to Borrowers Page 
 
All theses deposited in the Georgia State University Library must be used in accordance 
with the stipulations prescribed by the author in the preceding statement.  
 
The author of this thesis is:  
Student’s Name:  
Street Address:  
City, State, and Zip Code:  
The Chair of the committee for this thesis is:  
Professor’s Name:  
Department: Institute of Public Health 
College: Health and Human Sciences 
Georgia State University  
P.O. Box 3995  
Atlanta, Georgia 30302-3995  
Users of this thesis who not regularly enrolled as students at Georgia State University are 
required to attest acceptance of the preceding stipulation by signing below. Libraries bor-
rowing this thesis for the use of their patrons are required to see that each user records 
here the information requested. 
 
NAME OF USER ADDRESS DATE TYPE OF USE 
(EXAMINATION ONLY OR 
COPY) 
    
    
    
vii 
 
 
ACKNOWLEDGEMENTS 
 
 
This Thesis is dedicated first to Almighty God who gave me life and the ability to pursue the  
Master of Public Health (MPH) program. It is also dedicated to my wife, Chidinma Henshaw,  
and daughter, Nkesse Henshaw, for their undying supports and encouragements. I would like to  
thank the entire staff and faculty of the School of Public Health at Georgia State University for  
educating me for the past two years. I would especially like to acknowledge my thesis  
committee Chairperson, Dr. Ike Okosun, as well as my thesis committee member, Dr. Kim  
Ramsey-White for their time, support, guidance, and words of encouragement during this  
process. They are great! Lastly, I would like to express my gratitude to my friend, Mr. Reynolds  
Morrison, a Ph.D candidate, for his assistance during the process of this thesis. He is greatly  
appreciated. 
 5 
 
TABLE OF CONTENTS 
 
Title Page                                                                                                                     i 
Abstract                                                                                                                        ii 
Approval page                                                                                                             iii 
Copyright page                                                                                                            iv 
Dedication                                                                                                                    v 
Authors' statement page                                                                                               vi 
Notice to borrowers page                                                                                            vii 
Acknowledgement                                                                                                      viii 
Table of contents                                                                                                         ix 
List of tables                                                                                                                 x 
Chapter I Introduction                                                                                                   8 
 1.1 Background                                                                                           8 
 1.2 Criteria for testing for type 2 diabetes mellitus                                   11 
 1.3 Criteria for testing for GDM                                                                12 
 1.4 Purpose of study                                                                                   13 
 1.5 Research questions                                                                               13 
Chapter II Literature review                                                                                  14 
2.1 Background                                                                                          14 
2.2  Definition of GDM                                                                              15 
2.3 Pregnancy and diabetes                                                                         16 
2.4       Burden of GDM                                                                             18 
 6 
 
2.5       Diagnosing GDM                                                                                  19 
2.6           Race/ethnicity and GDM                                                                  19 
                                                                              
Chapter III Methods                                                                                         21 
3.1           Source of data                                                                      21                                                                                                            
3.2   Inclusion/exclusion criteria                                                   23 
3.3           Variables                                                                             23                                                                                               
3.3.a        Demographic variables                                                        23 
3.3.b        Other variables                                                                    25 
3.3.c          Definition of terms                                                            26 
3.3.d        Statistical method                                                                28 
Chapter IV Results                                                                                          29 
               4.1           Descriptive statistics                                                        29                       
Chapter V     Discussion                                                                                 42 
Weakness/limitations                                                                          45 
Clinical relevance                                                                                45 
Recommendations                                                                               46 
Conclusion                                                                                           46 
References                                                                                            47         
                                                                                        
 
 
 
 7 
 
                                                        
List of Tables 
 
Table 1: Demographic Characteristics in the General Population  
Table 2: Metabolic Profile in the General Population  
Table 3: Mean levels of metabolic factors among pregnant women 
Table 4: Metabolic Profile and Age by Diabetes Diagnosis among Pregnant Women 
Table 5: Demographic variables By Diabetes Diagnosis among Pregnant Women   
Table 5 (continued): Demographic and metabolic variables by diabetes diagnosis among preg-
nant women         
Table 6: Table 6: Differences in the prevalence of diabetes according to demographic and meta-
bolic variables stratified by race/ethnicity     
Table 6 (continued): Differences in the prevalence of diabetes according to demographic and 
metabolic variables stratified by race/ethnicity 
Table 7: Associations between metabolic profile, demographic variables and diabetes  
                   diagnosis  
Table Table 8: Stratification of the association between diabetes diagnosis and metabolic varia-
bles into race/ethnicity.  
 
 
 
 
 
 
 8 
 
Chapter I 
 
Introduction 
 
1.1 Background 
 
Diabetes mellitus (DM) is a metabolic disorder of multiple etiologies. It is characterized by 
chronic hyperglycemia with disturbances of carbohydrates, fat, and protein metabolism. The  
American Diabetes Association defines DM as a chronic illness that requires continuing medical 
care and ongoing patient self-management, education, and support to prevent acute complica-
tions and to reduce the risk of long-term complications (American Diabetes Association (ADA), 
2013b). This disorder results from defects in insulin secretion, insulin action, or both. Untreated, 
DM can be fatal. It carries an extensive burden (in the US, it affects 25.6 million people aged 25 
years and older, affects 12.6 million females age 20 years and older; costs over $174 billion in 
healthcare cost), and its incidence and prevalence is rapidly increasing worldwide (Centers for 
Disease Control & Prevention (CDC), 2011; ADA, 2013a). Chronic diabetes is associated with 
long-term damage, dysfunction, and multiple organ failure, especially the eyes, kidneys, nerves, 
heart, and blood vessels (ADA, 2010). There are different types of DM. However, the three most 
common types are: 1) Type 1 DM, characterized by lack of insulin production; 2) Type 2 DM, 
characterized by the inability of the pancreas to produce insulin; and, 3) Gestational DM, with 
onset during pregnancy.  
Type 1 DM, found usually in children and young adults, was previously known as insu-
lin-dependent diabetes mellitus (IDDM), or juvenile-onset diabetes mellitus. Characterized by 
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lack of insulin production, it manifests following the destruction of the pancreatic beta cells by 
the body’s immune system; the pancreatic beta cells are the only cells in the body that secretes  
insulin. Type 1 DM account for approximately 5% of all diagnosed cases of diabetes (CDC,  
2011; ADA, 2010). 
Type 2 DM, previously known as non-insulin diabetes mellitus (NIDDM), or adult-onset 
diabetes mellitus, is usually associated with older age, obesity, family history of diabetes, history 
of gestational diabetes, impaired glucose metabolism, physical inactivity, and race/ethnicity 
(Lowe et al, 2012). It is characterized by lack of insulin production, and begins as insulin re-
sistance. This type of diabetes account for approximately 90% to 95% of all diagnosed cases of 
diabetes (Leibson et al, 2001; Ferrara, 2007).  
African-Americans, Hispanic Americans, and American Indians are particularly at high 
risk for Type 2 DM and its complications (CDC, 2011). The long-term complications include:  
• Retinopathy 
• nephropathy leading to renal failure 
• peripheral neuropathy leading to foot ulcers 
• amputations, and Charcot joints 
• autonomic neuropathy leading to gastrointestinal 
• genitourinary 
• cardiovascular disease 
• sexual dysfunction 
• atherosclerotic  
• peripheral arterial disease 
• cerebrovascular disease 
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• and hypertension.  
Pathologic and functional changes in target organs, without any clinical symptoms, may be pre-
sent for a long time before diabetes is detected (ADA, 2010). 
Gestational diabetes mellitus (GDM) is a form of glucose intolerance diagnosed for the 
first time during pregnancy. GDM accounts for 90% of cases of DM in pregnancy, while preex-
isting Type 2 DM accounts for 8% of such cases (Saldana et al 2003; Black et al, 2013). GDM is 
a major medical complication of pregnancy. If untreated, the would-be mother and yet-to-be-
born child are likely to suffer morbidity and mortality (Seshiah et al, 2008; Kwik et al, 2007). 
Complications of DM in pregnancy include risk of preeclampsia, preterm birth, stillbirth, C-
section complications, birth defects, spontaneous abortion, and macrosomia. 3% to 5% of preg-
nancies are complicated by GDM (Makgoba et al, 2011). 
          Macrosomia is defined as birth weight above 90th percentile for gestational age or greater 
than 4000g (Kwik et al, 2007; Moore & Smith, 2013). Infants of women with preexisting DM 
experience double the risk of serious injury at birth, triple the likelihood of cesarean section de-
livery, and quadruple the incidence of newborn intensive care unit admission (Moore & Smith, 
2013). The newborn is likely to suffer other complications, such as transient hypoglycemia and 
hypocalcemia. If untreated, GDM carries a long-term sequelae for both mother and child: the 
mother is at risk for future type 2 diabetes, and the child is at risk for future obesity, insulin re-
sistance, and type 2 diabetes (Dornhorst & Frost, 2003). 
On the other hand, pregnancy can cause elevation of fasting plasma glucose, and results 
in fetal macrosomia, large for gestational age. African-American, Hispanic, Native American, 
and Asian women have higher prevalence of gestational diabetes than white women. Complica-
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tions of GDM differ among the various races/ethnicities: African-American women have lower 
rates of macrosomia despite similar levels of glycemic control; on the other hand, Hispanic 
women, even with aggressive management, have higher rates of macrosomia and birth injury 
than women of other ethnicities (Moore & Smith, 2013).  
1.2   Criteria for testing for Type 2 Diabetes Mellitus 
According to the American Diabetes Association “Standards of Medical Care in Diabetes” – 
2013, testing for type 2 diabetes in asymptomatic individuals should be considered in adults of 
any age who are overweight or obese(i.e., those with BMI ≥ 25 kg/m2) and who have one or 
more additional risk factors for diabetes. These risk factors include: 
• Physical inactivity 
• First-degree relative with diabetes 
• High-risk race/ethnicity (e.g., African-American, Hispanic/Latino, Native American,  
Asian American, Pacific Islander) 
• Women who delivered a baby weighing >9 lbs. or were diagnosed with GDM 
• Hypertension (greater than or equal to 140/90 mmHg or on therapy for hypertension) 
• HDL cholesterol level <35 mg/dL and/or a triglyceride level >250 mg/dL 
• Women with polycystic ovary syndrome 
• A1C ≥5.7%, IGT, or IFG on previous testing 
• Other clinical conditions associated with insulin resistance (e.g., severe obesity, 
acanthosis nigricans) 
• History of CVD 
In those without the risk factors, testing should begin at age 45. If the test for diabetes is 
normal, repeat testing in at least 3-year intervals. Appropriate tests for diabetes or prediabetes, 
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glycohemoglobin (HbA1C), fasting plasma glucose (FPG), or 75-g 2-hour oral glucose tolerance 
test (OGTT) (ADA, 2013b). 
 
1.3 Criteria for testing for Gestational Diabetes Mellitus 
 
         To diagnose GDM, the American Diabetes Association “Standards of Medical Care in Dia-
betes” – 2013 recommends: 
• Screen for undiagnosed type 2 diabetes at the first prenatal visit in those with risk fac-
tors, using standard diagnostic criteria;  
• Perform a 75-g OGTT, with plasma glucose measurement fasting and at 1- and 2-hour 
at 24-28 weeks of gestation in women not previously diagnosed with overt diabetes; 
• The OGTT should be performed in the morning after an overnight fast of at least 8  
Hours; 
• The diagnosis of GDM is made when any of the following plasma glucose values are 
exceeded (fasting: ≥ 92 mg/dL; 1-hour: ≥ 180 mg/dL; 2-hour: ≥ 153 mg/dL); 
• Screen women with GDM for persistent diabetes at 6-12 weeks postpartum, using  
OGTT and non-pregnancy diagnostic criteria; 
• Women with a history of GDM should have lifelong screening for the development of 
diabetes or prediabetes at least every 3 years; 
• Women with a history of GDM found to have prediabetes should receive lifestyle in-
terventions of metformin to prevent diabetes; (ADA, 2013b). 
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1.4 Purpose of Study 
Evidence suggests association between metabolic conditions (i.e. cholesterol, LDL, HDL, 
and triglyceride) and DM during pregnancy. However, data on the association across ra-
cial/ethnic groups is rare. This thesis will focus on a) examining differences in the metabolic pro-
files of pregnant women with prediabetes and diabetes; b) differences in the metabolic profiles of 
pregnantDM non-Hispanic Whites, non-Hispanic Blacks, and Mexican-Americans and Other 
races; c) the role of socioeconomic conditions in the relationship between pregnancy and DM, 
and d) the role of education in the relationship between pregnancy and diabetes. Additionally, 
this thesis will address healthy lifestyle choices, including nutrition, and physical activity. 
 
1.5 Research Questions 
1. What is the association between metabolic conditions (i.e., hypertension, BMI, choles-
terol, triglyceride, LDL, and HDL) and a positive diabetes diagnosis during pregnancy? 
2. Are differences in the above metabolic conditions attributable to racial/ethnic differ-
ences in the US?  
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Chapter II 
 
Literature Review 
 
2.1   Background 
Several studies have been conducted on diabetic pregnancy outcomes, but very few have 
been conducted on diabetic pregnancy in the different racial/ethnic groups. Evidence suggests 
association between metabolic conditions of DM (i.e., cholesterol, HDL, LDL, triglycerides, 
etc.) and pregnancy. However, data on the association across racial/ethnic groups is rare. 
Values for lipid levels during pregnancy and their changes with gestational age have not 
been studied substantially (Wiznitzer et al, 2009). This study will shed more light on the associa-
tion between lipid levels and GDM, especially its association across racial/ethnic groups.  
      The cause of GDM is multifactorial. Kwik et al, 2007 postulates that increase in estrogen and 
progesterone induces insulin production in the pancreas. These hormonal changes contribute to 
insulin resistance at the post-receptor level which results in higher blood glucose and free fatty 
acid levels in late pregnancy. Hyperglycemia in the mother causes fetal hyperglycemia, and 
hence fetal hyperinsulinemia. Insulin thus acts as a fetal growth factor, possibly resulting in 
macrosomia (Kwik et al, 2007). GDM alters the expression of placental genes related to markers 
and mediators of inflammation and leads to impaired fetal growth and programming, which 
causes several metabolic diseases (Sisino, et al, 2013). Women with GDM are at high risk of re-
currence of gestational diabetes and of developing DM in the future (Lawrence et al, 2008). 
Women’s risks of developing DM and metabolic syndrome are increased in the decade after de-
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livery, while their newborn infants are at increased risk of obesity and DM in adolescence and 
adulthood (Feig, 2012; Soma-Pillay, 2012; Chen et al,  2009). 
 
2.2  Definition of gestational diabetes mellitus (GDM)  
         The American Diabetes Association defines GDM as any degree of glucose intolerance 
with onset or first recognition during pregnancy (ADA, 2013b; Kaaja, & Greer, 2005). This def-
inition is irrespective of whether or not insulin is used for treatment, or diabetes continues after 
pregnancy. The glucose intolerance, characterized by fasting and post-prandial hyperglycemia, 
usually disappears after birth (Soma-Pillay, 2012).   
The criteria used in the diagnosis of GDM are not only designed to identify pregnant women 
who are at increased risk for perinatal outcomes but also to identify women who are at increased 
risk for the development of diabetes after pregnancy (Metzger et al, 2008).  
GDM is associated with persistent metabolic dysfunction in women at 3 years after deliv-
ery. It occurs in 2 to 9% of pregnancies with substantial risks of maternal and perinatal complica-
tions (Crowther et al, 2005). These perinatal risks include macrosomia, shoulder dystocia, bone 
fractures, nerve palsies, hypoglycemia, and death. The infants have risks of long-term adverse 
health outcomes such as sustained impairment of glucose tolerance, subsequent obesity, and im-
paired intellectual achievement (Makgoba et al, 2012; Crowther et al, 2005). In the United 
States, the rate of gestational diabetes has increased by 122% between 1989 and 2004 (Soma-
Pillay, 2012). 
Ben-Haroush et al (2004) suggested an association between several high-risk prediabetic 
states, GDM, and Type 2 diabetes (Ben-Haroush et al, 2004). Prediabetes is a condition that in-
cludes impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). Individuals whose 
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blood glucose levels are higher than normal but not high enough to qualify as diabetes are diag-
nosed as either impaired fasting glucose or impaired glucose tolerance. These individuals are at a 
higher risk of developing DM in the future. Pregnant women with pregestational diabetes are at 
increased risk for multiple complications affecting both mother and the fetus (U.S. Preventive 
Services Task Force (USPSTF), 2008). 
 
2.3  Pregnancy and diabetes 
Women who are obese, older than 25 years of age, have a family history of diabetes, have 
a history of previous GDM, or are of certain ethnic group (African-American, Hispanic, Ameri-
can Indian, or Asian) are at increased risk for developing gestational diabetes (Barr et al, 2002; 
CDC, 2013). Preconception care of diabetes can reduce the risk of congenital malformations, as 
the risk of malformations increases continuously with increasing maternal glycemia during the 
first 6-8 weeks of gestation.  
If diabetes is poorly controlled before conception and during the first trimester of preg-
nancy among women with type 1 diabetes, major birth defects can occur in 5% to 10% of preg-
nancies and spontaneous abortions in 15% to 20% of pregnancies; when diabetes is poorly con-
trolled in the second and third trimesters of pregnancy, excessively large babies (macrosomia) 
can result (CDC.gov).  
Screening is generally performed with oral glucose tolerance test OGTT), fasting plasma 
glucose (FPG), and glycohemoglobin (HbA1C). OGTT is performed after an overnight fasting 
with 75-gm dose of glucose; plasma glucose is measured fasting. HbA1C reflects average 
glycemia over an interval of several weeks (ADA, 2010). It is desired that HbA1C levels be as 
close to normal as possible (<7%) in an individual patient before conception is attempted (ADA, 
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2013b). In early pregnancy (i.e., first trimester and first half of second trimester) fasting and 
postprandial glucose tolerance are normally lower than in non-pregnant women, which may re-
flect the presence of undiagnosed preconception diabetes (Alberti & Zimmet, 1998).  
There is a continuum of risk for adverse maternal and fetal outcomes as the maternal glu-
cose level rises (Ben-Haroush et al, 2004). In order to provide the opportunity to optimize preg-
nancy outcome, it is desirable to detect overt diabetes in early pregnancy as early as possible, 
using OGTT, FPG, and HbA1C to perform this task. The recommendation to use of HBA1C to 
diagnose and identify people at increased risk for developing diabetes has been endorsed by the 
ADA because it does not require a fasting state, reflects the usual level of glycemia for a period 
of 3-4 months, has low intraindividual variability, and is a good predictor of diabetes-related 
complications (Lowe et al, 2012). HbA1C is significantly lower in early pregnancy and further 
lowered in late pregnancy when compared to age-matched nonpregnant women. The normal 
range of HbA1C in nonpregnant women is 4.7% - 6.3%, 4.5% - 5.7% in early pregnancy, and 
4.4% – 5.6% in late pregnancy (Ben-Haroush et al, 2004).   
In the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study (2008), in which  
25,505 pregnant women at 15 centers in 9 countries underwent 75-gm of oral glucose tolerance 
testing at 24-32 weeks of gestation, risks of some adverse outcomes were low when FPG was ≤ 
4.4 mmol/l (80 mg/dl) ((Metzger, et al, 2008; ADA, 2010). Five to ten percent of women with 
GDM have the risk of developing Type 2 DM after delivery, while the probability of developing 
diabetes ranges between 20% to 50% in women with GDM in the 5 to 10 years following preg-
nancy (Zhang et al, 2009; Lindsay, 2009). 
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2.4  Burden of Gestational Diabetes Mellitus 
The prevalence of GDM increases with increasing maternal age, rising from 1.3% of 
pregnancies in women younger than age 21 to 8.7% of pregnancies of women older than age 35 
(Lindsay, 2009). Prepregnancy obesity is associated with the development of GDM, as 65% to 
75% of women with GDM are obese (Black, et al, 2013).  
According to the U.S. Preventive Services Task Force, the current prevalence of gesta-
tional diabetes in the United States ranges from 1% to 9% (USPSTF, 2008). The reason for this 
increased prevalence includes the rise in obesity, rise in maternal age, and changes in lifestyles 
(Feig, 2012; Lie et al, 2013). GDM is associated with an economic burden on the US govern-
ment. In the United States, significant economic burdens are associated with prediabetes and 
GDM. Timothy et al, (2010) wrote that nearly fifty-seven million adults have prediabetes, a con-
dition associated with $25 billion annually in higher medical cost. Additionally, gestational dia-
betes affects 4.5 percent of all pregnancies (180,000 cases in 2007) at an associated cost of $636 
million (Timothy et al, 2010). Of this total cost, about 36% is paid by government programs 
(primarily Medicaid), 56% by private insurance, and 8% by self-pay and charity care (Chen, et 
al, 2009). Indirect costs associated with GDM include increased time off from work or school, 
psychological stress, and reduced performance by offspring in school (Chen et al, 2009). 
GDM significantly increases the rates of in-hospital admission for cesarean delivery, 
preeclampsia, ecclampsia, and other maternal complications of pregnancy. It is also associated 
with a statistically significant increase in newborns’ ambulatory visits for macrosomia, or 
birthweight above the 90th percentile, endocrine and metabolic disturbances, labor and delivery 
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on the newborn (Timothy et al, 2010), as well as neonatal intensive care unit admission (Zhang et 
al, 2009). 
2.5  Diagnosing Gestational Diabetes Mellitus 
Healthy pregnant women have low HbA1C, particularly in the first half of their pregnan-
cy. For the prevention of congenital malformations and macrosomia, it is desirable that HbA1C 
in pregnant women be below 5% in the first trimester, and below 6% in the third trimester. Most 
screening is conducted between 24 and 28 weeks' gestation; there is little evidence about the val-
ue of earlier screening (Barr et al, 2002; Radder & Roosmalen, 2005). GDM is also diagnosed in 
early pregnancy when one or more of the following values are true: fasting plasma glucose 
(FPG) is ≥ 5.1 mmol/l (92 mg/dl); 1-hr plasma glucose ≥10.0 mmol/l (180 mg/dl); or 2-hr plasma 
glucose ≥8.5 mmol/l (153 mg/dl) (ADA, 2010). HbA1C levels vary with patient’s race/ethnicity, 
with African-Americans having higher rates of glycation; African-Americans, with or without 
diabetes, have higher levels HbA1C than non-Hispanic whites when matched for FPG (ADA, 
2013). Women with early diagnosis of GDM, especially in the first half of pregnancy, represent a 
high-risk subgroup, with an increased incidence of obstetric complications, recurrent GDM in 
subsequent pregnancies, and future development of Type 2 diabetes (Ben-Haroush et al, 2004). 
2.6 Race/Ethnicity and Gestational Diabetes 
The prevalence of GDM has increased over time with the increase of obesity. In the Unit-
ed States, approximately 135,000 cases of GDM are diagnosed annually. This represents 3% to 
8% of all pregnancies, and varies in prevalence among different racial/ethnic groups (Dabalea et 
al, 2005). Higher prevalence is seen among Native-American, African-American, Asian, and 
Hispanic populations than among Non-Hispanic whites; the prevalence of GDM is two-fold 
higher in women of other ethnic backgrounds, than in non-Hispanic whites (Dabalea et al, 
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2005). In a New York study of gestational diabetes mellitus from 1990 – 2001, a rapid increase 
of GDM prevalence was seen among most racial/ethnic groups, especially among Asians, Mexi-
cans, and non-Hispanic Black women (Thorpe, et al, 2005; Hedderson et al, 2012). 
The two strongest independent risk factors for GDM are race/ethnicity and obesity. The 
overall prevalence of GDM varies by race/ethnicity, lowest among non-Hispanic Blacks and 
non-Hispanic Whites (4.4% and 4.5%, respectively); intermediate among Hispanic (6.8%); and 
highest among Asians (10.2%) (Hedderson et al, 2012). Obesity is highest among African- 
Americans and lowest among Asians (Hedderson et al, 2012). Other risk factors for GDM in-
clude: maternal age ≥30, family history of DM, previous history of GDM, previous history of 
macrosomia, glycosuria, and obesity (Kashinakunti et al, 2013). Education is also a risk factor: 
Asian women are more educated and less likely to be overweight (BMI >25.0 kg/m2) or obese 
(BMI >30.0 kg/m2) as compared to women of other racial/ethnic groups (Hedderson et al, 2012). 
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Chapter III 
Methods 
3.1 Source of Data 
          National Health and Nutrition Examination Survey (NHANES) 1999-2010 is the source of 
this data for this study.  NHANES studies health and nutritional status of adults and children in 
the United States. This 1999-2010 study is a stratified multistage probability sampling design 
used to select a representative sample of the civilian non-institutionalized population of the US 
(CDC, 2013). This excludes all persons in supervised care or custody in institutionalized settings, 
all active –duty military personnel, active-duty family members living overseas, and any other 
citizens residing outside the 50 States and the District of Columbia (National Health and Nutri-
tion Examination Survey (NHANES), 2013). 
NHANES was started in the early 1960s. Since then, it has conducted a series of surveys 
focusing on different population groups or health topics. The information obtained from the sur-
veys is used in determining the prevalence of major diseases and their risk factors; it is also used 
in assessing nutritional status and its association with health promotion and disease prevention 
(CDC, 2013). In addition, data obtained from the surveys is used in epidemiological studies and 
health sciences research. Information obtained from the current survey is compared with those 
obtained from previous surveys to allow planners to detect the extent various health problems 
and their risk factors have changed in the population over time (CDC, 2013). In selecting partici-
pants, NHANES used a statistical process, using the most current census information, to divide 
the United States into communities that are further divided into neighborhoods; housing units are 
selected randomly from each neighborhood for interviews and for determination of  
eligibility for the study (NHANES, 2013).  
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Starting in 1999, NHANES began interviewing a nationally representative sample of ap-
proximately 5,000 persons each year (NHANES, 2013). These persons are located in counties 
across the US. In a single year, about 15 counties are selected out of approximately 3,000 coun-
ties in the United States (NHANES, 2013).   
As a major program under the National Center for Health Statistics (NCHS), NHANES conducts 
its survey by combining health interviews and physical examinations. The interviews include 
demographic, socioeconomic, dietary and health-related questions; while the physical examina-
tion component includes medical, dental, and physiological measurements, as well as laboratory 
tests administered by highly trained medical personnel. NCHS is responsible for producing vital 
and health statistics for the nation (CDC, 2013). It is a part of the Centers for Disease Control 
and Prevention (CDC). 
NHANES conducted the 1999-2010 interviews in respondents’ homes by trained inter-
viewers using the Computer-Assisted Personal Interviewing (CAPI) system. Interview questions 
on reproductive health including menstrual history, pregnancy history, lactation, oral contracep-
tive and hormone replacement therapy use, were asked (CDC, 2013). The interviews were con-
ducted in-person with an interviewer in English or Spanish, as selected by survey participants, or 
with translators as requested (CDC, 2013). Also, many of NHANES interviewers are bilingual. 
Information collected from participants is kept in strict confidence.  
The 1999-2010 health measurements were performed in specially-designed and equipped 
mobile centers that travel to locations throughout the country (CDC, 2013). As in past health ex-
amination surveys, NHANES collects data on the prevalence of chronic disease conditions in the 
population. Through the survey, estimates for previously undiagnosed conditions as well as those 
known and reported by respondents are produced (CDC, 2013). Such information is of a particu-
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lar strength to the NHANES program. Data collected from such surveys indicates that undiag-
nosed diabetes is a significant problem in the United States. To this end, government and private 
agencies have intensified efforts to increase public awareness, especially among minority popu-
lations (NHANES, 2013). NHANES is designed to sample larger numbers of certain subgroups 
of particular interest to public health. Oversampling is done to increase reliability and precision 
of estimates of health status indicators for the population subgroups. For the 2007-2010 admin-
istration of NHANES, all Hispanic persons were oversampled, rather than just Mexican-
American Hispanic persons (NHANES, 2013) 
NHANES also uses data collected in surveys to assess nutritional status and its associa-
tion with health promotion and disease prevention. The NHANES data also used in epidemiolog-
ical studies and health sciences research, which helps to develop sound public health policy, di-
rect and design health programs and services, and expand the health knowledge for the nation. 
Survey findings are also the basis for national standards for such measurements as height, 
weight, and blood pressure (CDC, 2013). 
3.2 Inclusion and Exclusion Eligibility Criteria  
Individuals were included in the study if laboratory test results for pregnancy were posi-
tive.  Females 20 – 44 years of age were eligible to participate. For this study, however, females 
18 – 45 years of age were included. Patients who had prediabetes and diabetes were combined to 
increase the sample size. 
3.3 Variables 
3.3.a  Demographic variables 
The demographic variables included in this study were age, race/ethnicity, education, and 
household income. Age: this is the respondent’s age (in years) at screening interview. Respond-
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ent’s actual or imputed date of birth was used in the calculation (CDC, 2013). NHANES reported 
ages 1 to 79 for survey participants. If the year of birth is missing, or not given, NHANES com-
puted it as the year of screening interview minus the age in years provided by the respondent 
during the screening interview (CDC, 2013). In my study, women ages 18 years to 45 years are 
included.  
Race/ethnicity: This variable is derived from responses to the survey questions on race. 
The different races reported on NHANES survey are non-Hispanic whites, non-Hispanic blacks, 
Mexican-American (as self-identified), other Hispanics (as self-identified), and other races (self-
identified) (CDC, 2013). Missing values were eliminated. Four categories for these variables: 
non-Hispanic white, non-Hispanic black, Mexican-American, and “Other” races [which include 
other Hispanics and participants from other races (including multi-racial)] were used in this 
study.  
Education: This is for adults 20 years and older. This is the highest level of education 
completed or highest degree received. NHANES categorized this into: less than 9th grade educa-
tion, 9-11th grade education (which includes 12th grade and no diploma), High school gradu-
ate/GED or equivalent, some college (or associate degree), and college graduate or above (CDC, 
2013).    
          Income: this is the estimated total annual household income, reported in dollars. Family  
income was used if the household is comprised of only a single family. If more than one family  
resided in the household, income data by each family interviewed was used (CDC, 2013).  
However, some respondents refused to provide their income information, while others had little 
or no knowledge of family income (CDC, 2013). 
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3.3.b Other variables 
            Reproductive questions asked during the interview included: 1) “Are you pregnant now?” 
2) “During pregnancy, told you have diabetes?” (CDC, 2013). Diabetes questions included: 
“Doctor told you have diabetes?”, “Ever told you have prediabetes?”, “Taking insulin now?”, 
and Take diabetic pills to lower blood sugar?” (CDC, 2013). 
Pregnancy status: this is at time of exam. Women between the ages 20 years and 44 years 
at the time of the mobile examination centers examination were included (CDC, 2013). Pregnant 
women who were outside of this range were not reported due to disclosure concerns (CDC, 
2013). Values included in the survey report are from urine pregnancy test and self-reported preg-
nancy status (CDC, 2013).  
BMI: body mass index, reported in Kg/m2. The 2009-2010 data were reviewed for unu-
sual and erroneous values (CDC, 2013). Values that were above the 99th percentile or below the 
1st percentile were flagged for review; if determined to be unrealistic, they were deleted from the 
file (CDC, 2013).  Blood pressure: systolic and diastolic blood pressure measurements (in 
mmHg). Prior to taking blood pressure measurements, participants rested quietly in a sitting po-
sition for 5 minutes, after which 3 consecutive blood pressure readings were obtained (CDC, 
2013).  
Three of the diabetes measures used in assessing diabetes mellitus include fasting plasma 
blood glucose (FPG), oral glucose tolerance test (OGTT), and glycohemoglobin (HbA1C). 
OGTT was added to the laboratory protocol in 2005 (NHANES, 2013). A fasting glucose test was 
performed on all participants after a 9-hour fast (NHANES, 2013). Participants were required to 
drink a calibrated dose of Trutol (75 grams of glucose) after the initial venipuncture, and to have 
a second venipuncture 2 hours after consuming the Trutol (NHANES, 2013).  Exclusion criteria 
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include hemophilia and chemotherapy safety exclusions, fasting less than 9 hours, taking insulin 
or oral hypoglycemic agents, refusing phlebotomy, and not taking the entire Trutol solution with-
in the allotted time (NHANES, 2013). Glycohemoglobin: (HbA1C), reported in percentage (%). 
Fasting plasma glucose (FPG), reported in mg/dL. It is measured in the morning examination 
session only. 2-hour glucose tolerant test: (OGTT), reported in mg/dL. It is measured in the 
morning examination session only. 
Data on blood lipid levels are essential in monitoring the status of hyperlipidemia. Dura-
tion of fasting (≥ 8.5 hours) and the time of the day of the venipuncture were recorded 
(NHANES, 2013). Lipid measurement is used to screen for atherosclerotic risk as well as lipid 
and lipoprotein metabolic disorders (NHANES, 2013). The lipid and lipoprotein variables meas-
ured include: 
Total cholesterol, measured in mg/dL 
HDL cholesterol, measured in mg/dL 
LDL cholesterol, measured in mg/dL 
Triglyceride, measured in mg/dL. Elevated triglyceride measurements are associated with diabe-
tes mellitus and other diseases (NHANES, 2013). 
 3.3.c  Definition of terms   
Glycohemoglobin (HbA1C): This reflects the average blood glucose over a 2-3 month 
period. It has been used to evaluate the treatment of diagnosed diabetes mellitus (Hjellestad et al, 
2013). A value ≥6.5% is used for the diagnosis of DM (ADA, 2013c; WHO, 2013). Fasting 
plasma blood glucose: Used in the diagnosis of DM. defined as fasting plasma glucose ≥126 
mg/dl (ADA, 2013b; Hjellestad et al, 2013). Oral glucose tolerance test: Level of ≥200mg/dl is 
one of the criteria used in the diagnosis of DM (Hjellestad et al, 2013; ADA, 2013b).  
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Hypertension: defined as blood pressure ≥140/90 mmHg, or taking antihypertensive  
medications (Ong et al, 2007). The goal is to reduce blood pressure levels <140/90 mmHg  
and lower in those with diabetes (Lenfant et al, 2003). Diabetes: Defined as random plasma glu-
cose >200 mg/dl, and HbA1c >2 standard deviation above the laboratory mean (Barr et al, 
2002). Prediabetes: Diagnosed when FPG is 100 mg/dl-125mg/dl (impaired fasting glucose), or 
2-h plasma glucose in the 75-g OGTT is 140 mg/dl-199 mg/dl (impaired glucose tolerance), or 
HbA1c is 5.7%-6.4%. These individuals have increased risk for developing diabetes (ADA, 
2013b). Gestational diabetes mellitus (GDM): Defined as glucose intolerance that is first detect-
ed during pregnancy. It has variable severity: in some women, homeostasis is restored shortly 
after delivery, while others remain at high risk for the development of type 2 DM in the future 
(Bellamy et al, 2009; Schmidt et al, 2001). GDM is diagnosed when: FPG ≥92 mg/dl, OGTT (1-
h plasma glucose) ≥180 mg/dl, or OGTT (2-h plasma glucose) ≥153mg/dl (ADA, 2013b). 
Body Mass Index (BMI): This is a simple index of weight-for-height used commonly to 
classify underweight, overweight, and obesity in adults. It is defined as weight in kilograms di-
vided by the square of the height in meters (kg/m2) (WHO, 2006). It is classified as: underweight  
(<18.5 kg/m2), normal weight (18.5 kg/m2 -24.99 kg/m2) , overweight (25 kg/m2-29.99 kg/m2), 
and obese (≥30 kg/m2) (WHO, 2006). 
Desirebale total cholesterol level is <200 mg/dl; borderline high is 200 mg/dl-239 mg/dl; 
and high is ≥240 mg/dl (National Cholesterol Education Program (NCEP) 2001). HDL choles-
terol is considered low at levels ≤40 mg/dl; high at ≥60 mg/dl (NCEP, 2001). Optimal LDL cho-
lesterol is <100 mg/dl; high at 160 mg/dl-189 mg/dl; very high ≥190 mg/dl (NCEP, 2001). Nor-
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mal triglyceride is <150 mg/dl; borderline high at 150 mg/dl-199 mg/dl; high 200 mg/dl-499 
mg/dl; very high ≥400 mg/dl (NCEP, 2001). 
3.3.d  Statistical Method 
Statistical Analysis System 9.2 version (SAS 9.2) was used in setting and analyzing data, 
including the mean, standard deviation, odds ratio, confidence intervals, and p-values. P<0.05 
was used to establish statistical significance. Descriptive statistics were derived for the demo-
graphic variables using SAS 9.2. SAS 9.2 version was also used to run univariate logistic regres-
sion analysis to determine the association between metabolic variables (BMI, cholesterol, LDL, 
HDL, triglyceride, hypertension) among pregnant diabetic women.   
Logistic regression analysis was used to determine the likelihood of being diagnosed with 
DM, provided the patient has the metabolic conditions. It was also used to determine the 
likelyhood of being diagnosed with GDM stratified by race/ethnicity, age, income, and educa-
tion.  
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Chapter IV 
Results 
4.1 Descriptive Statistics 
The sample size for the study is 1417, of which 114 (9.3%) were diagnosed with diabetes. 
Table 1 shows the demographic characteristics of the sample. Among the respondents (N=1417), 
approximately 39% (n= 616) were between ages 18-25 years, 687 (48.9%) were between ages 
26-35 years, while 110 (1.6%) are between ages 36-45 years. Non-Hispanic whites made up the 
majority racial/ethnic group (52.9%), followed non-Hispanic blacks (15.6%) and Mexican-
Americans (16%), and 168 (15.5%) represent “Other” racial groups. Nearly 22% had less than 
high school education, 20% were high school graduates, and 58% had at least some college edu-
cation.  
Table 1: Demographic Characteristics in the General Population (N=1417) 
 
 
 
 
           
In Table 2, majority of the respondents were overweight (66.9%). A total of 127 (9.0%) 
had hypertension, 619 (39.1%) had elevated total cholesterol, 397 (25.7%) had elevated low den-
Variable N % (SE) 
 
Diabetes 
  
Yes 114 9.3 
No 
 
1303 90.7 
Race/Ethnicity   
NH Whites 620 52.9 
NH Blacks 219 15.6 
Mex-Americans 420 16.0 
Others 
 
168 15.5 
Age (years)   
18-25 616 39.5 
26-35 687 48.9 
36-45 
 
110 11.6 
Education   
<HS 395 21.6 
HS Graduate 300 20.1 
At least College 667 58.3 
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sity lipoprotein (LDL), 1028 (68.15%) had low high density lipoprotein (HDL), while 359 
(20.96%) had elevated triglycerides. The mean levels of total cholesterol, LDL, HDL, Triglycer-
ides, and BMI are also shown in Table 3.   
 
Table 2: Metabolic Profile in the General Population  
Variable N % (SE) 
 
BMI  
  
Underweight 124 7.4 
Normal 359 25.8 
Overweight 934 66.9 
 
Hypertension                            
Yes 127 9.0 
No 1290 91.0 
 
Total Cholesterol    
Low 798 61.9 
Elevated 619 39.1 
 
HDL   
Low 1028 68.2 
Elevated 389 31.9 
 
LDL   
Low 1020 74.4 
Elevated 397 25.7 
 
Triglycerides   
Low 1058 79.1 
Elevated 359 21.0 
 
 
Table 3: Mean levels of metabolic factors among pregnant women 
 
Variable N Mean (SE) 95% CI 
 
Total cholesterol 986 212.6 (2.7) 207.2-217.9 
 
HDL 450 67.0 (1.1) 65.8-69.2 
 
LDL 596 114.8 (2.1) 110.6-118.9 
 
TG 640 160.3 (4.6) 151.0-170.0 
 
BMI 1315 29.1 (0.3) 28.5-29.7 
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        Tables 4 show the mean values for metabolic conditions stratified across diabetes status. As 
shown there were statistically significant differences between pregnant diabetic women and 
pregnant non-diabetic women in terms of mean total cholesterol level [(210 vs. 221) 
(p<0.0001)]; mean LDL cholesterol [(105 vs.122) (P<0.0001)]; mean HDL cholesterol [(62 vs. 
69) (P<0.0001)]; mean triglyceride level [(190.4 vs. 178.4) (P<0.0001)]; and mean BMI [(32.3 
vs. 28.7) (P<0.0001)];                                               
Table 4: Metabolic Profile by Diabetes Diagnosis Among Pregnant Women 
 
Diabetes Diagnosis  
Variable Yes No P-value 
 n Mean (SD) n Mean (SD) 
 
 
Total Cholesterol (mg/dL) 97 210.0 (53.2) 889 221.4 (50.3) <0.0001 
 
LDL Cholesterol (mg/dL) 88 104.7 (35.9) 508 122.0 (40.1) <0.0001 
 
HDL Cholesterol (mg/dL) 56 61.7 (16.2) 394 69.4 (16.8) <0.0001 
Triglycerides (mg/dL) 101 190.4 (102.2) 539 178.4 (86.6) <0.0001 
Avg. BMI (kg/m2) 110 32.3 (8.3) 1205 28.7 (6.5) <0.0001 
 
 
Table 5 shows proportions of pregnant diabetic versus pregnant non-diabetic women in 
the population across various demographic and metabolic variables. Only about 40% of pregnant 
diabetic women had at least some college education, when compared to 60% of those who have 
not been diagnosed with diabetes (p=0.0294). Similarly, 86.9% of pregnant diabetic women were 
overweight/obese when compared to 64.8% of pregnant non-diabetic women (p<0.0001) as were 
51.0% of pregnant diabetic women with elevated levels of LDL versus 23% of non-diabetic 
pregnant women (p=0.0001); and 36.9% of pregnant diabetic women with elevated levels of tri-
glyceride versus 19.3% of non-diabetic pregnant women (p=0.0036). There were no significant 
associations between diabetes and race/ethnicity (p=0.1423), age levels (p=0.7074), hypertension 
diagnosis (p=0.6312), HDL levels (p=0.1169), or total cholesterol levels (p=0.9183). 
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     Table 5: Demographic and metabolic variables by diabetes diagnosis among pregnant women 
  
Variable Yes No P-value 
 
 
 
 N                % (SE) N % (SE) 
 Education   
Less than High School 37 36.0 (7.6) 358 20.1 (1.7)  
 
0.0294 HS Grad 30 24.0 (6.8) 270 19.7 (1.8) 
At least college 43 39.9 (7.2) 624  60.2 (2.1) 
Race/Ethnicity    
 
 
 
0.1423 
NH White 45 45.6 (7.0) 575 53.6 (2.6) 
NH Blacks 14 12.2 (3.6) 205 16.0 (1.8) 
Mexican-American 39 23.5 (4.9) 371 15.2 (1.4) 
“Other” Races 16 18.7 (5.7) 152 15.2 (2.0) 
Age (years)      
18-25 43 44.1 (7.9) 573 39.0 (2.1)  
26-35 51 42.8 (7.8) 636 49.6 (2.6) 0.7074 
36-45 19 13.1 (3.3) 91 11.5 (1.9)  
Hypertension (mmHg)    
 
 
0.6312 
Yes 13 10.9 (4.5) 114 8.82 (1.4) 
No 101 89.1 (4.5) 1189 91.2 (1.4) 
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Table 5 (continued): Demographic and metabolic variables by diabetes diagnosis among pregnant women 
 
 BMI (kg/m2) 
 
   
 
 
 
 
 
 
 
<0.0001 
Underweight 5 1.5 (0.7) 119  8.0 (1.5) 
Normal 13 11.7 (4.6) 346 27.2 (2.0) 
Overweight 96 86.9 (4.6) 838 64.8 (2.1) 
Tot. Cholesterol (mg/dL)      
Low 62 61.3 (6.0) 736 62.0 (2.3)  
Elevated 52 38.7 (6.0) 567 38.1 (2.3) 0.9183 
LDL  (mg/dL)      
Low 69 49.1 (7.5) 951 77.0 (2.1)  
Elevated 45 51.0 (7.5) 352 23.1 (2.1) 0.0001 
HDL (mg/dL)      
Low 73 59.7 (6.2) 955 69.0 (2.1)  
Elevated 41 40.3 (6.2) 348 301.0 (2.1) 0.1169 
Triglycerides (mg/dL)      
Low 54 63.1 (5.6) 1004 80.7 (1.8)  
0.0036 
Elevated 60 36.9 (5.6) 299 19.3 (1.8)  
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           Table 6 shows differences in demographic and metabolic characteristics among the preg-
nant diabetic versus pregnant non-diabetic women stratified by race/ethnicity. Among non-
Hispanic whites, significant differences in terms of education levels (p=0.0155), LDL levels 
(p=0.0035) and BMI (p<0.0001) were observed.   For instance, pregnant women with diabetes 
had a higher prevalence of overweight/obese (86.9%) when compared to those who were of 
normal weight (11.7%). Also, pregnant women who were diabetic had a higher prevalence of 
elevated LDL levels (54.3%) when compared to those without diabetes (23.4%). 
Among non-Hispanic blacks (Table 6), significant differences were observed in terms of 
education levels (p=0.0015), BMI (p<0.0001), triglyceride levels (p=0.0193), and HDL levels 
(p=0.0194). For instance, nearly 94% of individuals who were diagnosed with diabetes were 
overweight/obese when compared to 70% of those who had a negative diabetes diagnosis. Simi-
larly, 36.9% of pregnant diabetic individuals had less than a high school education, when com-
pared to 26.0% the non-diabetic pregnant population.  
Among Mexican-Americans, significant differences among the diabetic and non-diabetic 
groups were observed in terms of educational levels (p=0.0102), BMI (p<0.0001) and triglycer-
ide levels (<0.0001). Within this race/ethnic group, 93.9% of individuals with diabetes were 
overweight/obese compared to 69.6% of non-diabetic pregnant women. Also, over 60% of dia-
betic pregnant women had elevated levels of triglycerides compared to 19% of non-diabetic 
pregnant women. Education, blood pressure, total cholesterol, and LDL were not significantly 
associated with diabetic pregnancy.  
 Among “Other” races/ethnicities, education (P=0.0173), age (P<0.0001), LDL  
 (P=0.0007), and low HDL (P=0.0227) were significantly associated with diabetes during preg-
nancy. Approximately 58% of diabetic pregnant women had less than high school education 
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compared to just over 25% of non-diabetic pregnant women. Within this race category, 70% per-
cent of diabetic pregnant women have elevated LDL levels compared to 21.0% of non-diabetic 
pregnant women. Also, 79.9% of diabetic pregnant women had low HDL compared to 67.0% of 
non-diabetic pregnant women. No other significant associations were observed within this group. 
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Table 6: Differences in the prevalence of diabetes according to demographic and metabolic variables stratified by race/ethnicity 
   NH-Whites NH- Blacks Mexican- Americans “Other” Races 
Variables Yes No P-value Yes  No P-value Yes No P-value Yes No P-value 
N 
(%SE) 
N (%SE)  
 
N (%SE) N (%SE)  
 
N (%) N 
(%SE) 
 
 
N (%SE) N (%SE)  
 
Education  
 
 
 
 
0.0155 
  
 
 
 
 
0.0015 
  
 
 
 
 
0.9726 
  
 
 
 
 
0.0173 
  <HS 6    
18.5 
(10.1) 
57    
7.3  
(2.2) 
4     36.9 
(11.7) 
63     
26.0 
(3.2) 
19                        
52.4 
(12.2) 
199                
55.2 
(3.6) 
8 
58.1 
(12.0) 
39 
25.1  
(3.7) 
HS Grad 13    
26.5 
(9.6) 
116    
18.3 
(2.2) 
6      
42.8 
(11.7) 
48     
26.3 
(3.3) 
10                     
27.7 
(10.4) 
82                        
25.3 
(3.3) 
1 
1.4 
(1.5) 
24 
12.2  
(1.9) 
At least 
college 
25    
 55.0 
(6.9) 
390   
74.4 
(2.8) 
4        20.3 
(5.0) 
90     
47.7 
(3.9) 
7               
19.9  
(5.6) 
60                    
19.5 
(2.8) 
7 
40.4 
(12.2) 
84 
62.7  
(3.3) 
Age (years)  
 
 
 
 
0.0816 
  
 
 
 
 
0.1762 
 
  
 
 
 
 
0.0102 
  
 
 
 
 
<0.0001 
18-25 17    
41.9 
(10.7) 
204    
35.9 
(3.2) 
8           
65.3 
(12.5) 
123    
55.2 
(3.7) 
13                         
24.6  
(7.1) 
201                   
50.0 
(1.9) 
5 
59.8 
(9.5) 
45 
21.72 
(4.09) 
26-35 23    
54.1 
(11.0) 
322   
50.3 
(3.2) 
3             
18.0 
(10.9) 
73     
40.2 
(3.7) 
18               
55.0  
(7.5) 
151                       
44.5 
(2.3) 
7 
16.3 
(4.1) 
90 
62.1  
(5.3) 
36-45 5      
4.01 
(2.1) 
48     
13.9 
(2.6) 
3             
16.7 
(10.2) 
9            
4.58 
(1.6) 
7                 
20.4  
(8.0) 
18                
5.5 (1.3) 
4 
24.0 
(7.6) 
16 
16.2  
(2.4) 
Blood Pressure (mmHg)  
 
 
 
0.0678 
  
 
 
 
0.2921 
  
 
 
 
0.9562 
  
Normal 36     
84.9 
(3.2) 
518     
91.0 
(1.7) 
12           
75.7 
(13.5) 
179         
87.5 
(2.2) 
37 
95.5 (3.3) 
352 
95.7 
(1.3) 
16 
100 
(0.00) 
140 
91.4  
(1.6) 
Hyperten-
sive 
9      
15.1 
(3.2) 
57     
9.0 
(1.7) 
2            
24.3 
(13.5) 
26            
12.5 
(2.12) 
2              
4.5  
(3.3) 
19 
4.4 (1.3) 
0    . 12 
8.6  
(1.6) 
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Table 6 (continued): Differences in the prevalence of diabetes according to demographic and metabolic variables stratified by 
race/ethnicity 
Variables NH-Whites NH- Blacks Mexican- Americans “Other” Races 
 Yes No P-value Yes No P-value Yes No P-value Yes No P-value 
 N 
 (%SE) 
N  
(%SE) 
 N  
(%SE 
N  
(%SE 
 N  
(%SE) 
N  
(%SE) 
 N  
(%SE) 
N 
 (%SE) 
 
BMI   (kg/m2)  
 
 
 
<0.0001 
  
 
 
 
<0.0001 
  
 
 
 
<0.0001 
  
Under-
weight 
2       
1.6 
 (0.8) 
64       
 9.9 
 (2.3) 
1            
2.83 (0.65) 
15          
5.3  
(1.2) 
2 
1.5  
(1.0) 
26 
3.7  
(1.4) 
0    . 14 
8.16  
(2.6) 
Normal 8        
11.5  
(6.4) 
176     
30.2 
(3.00) 
1           
2.6  
(0.6) 
50         
23.8  
(2.9) 
1 
4.55  
(0.8) 
79 
26.7 
(2.8) 
3 
26.9 
(14.3) 
41 
21.0  
(3.1) 
Overweight 35     
86.8  
(6.4) 
335       
59.9  
(2.7) 
12         
94.6 
 (1.2) 
140      
70.9  
(2.9) 
36 
93.9 
 (1.1) 
266 
69.6 
(2.5) 
13 
73.1  
(14.3) 
97 
70.8 
(3.5) 
Tot.  cholesterol  
 
 
0.6206 
  
 
 
0.1541 
  
 
 
0.3086 
  
 
 
0.4713 
Low 19     
58.2  
(8.0) 
307    
62.9  
(3.5) 
11     
73.1 
(6.4) 
127            
62.3 
 (3.2) 
22 
64.5 
 (8.9) 
208 
54.1 
(2.4) 
10 
56.9 (11.9) 
94 
66.6 
 (3.3) 
Elevated 26     
41.8  
(8.0) 
268    
37.1 
(3.5) 
3      
26.9 
(6.4) 
78 
37.8 
(3.2) 
17 
35.5 
 (8.9) 
163 
45.9  
(2.4) 
6 
43.0  
(11.9) 
58 
33.9  
(3.3) 
LDL  
 
 
0.0035 
  
 
 
0.7220 
  
 
 
0.1117 
  
 
 
0.0007 
 
Low 25       
45.7 
(11.0) 
407    
76.6 
 (2.3) 
12       
75.4  
(10.6) 
161     
79.2 
(3.2) 
23 
57.3 
(9.7) 
264 
73.8  
(2.6) 
9 
29.6 
(9.7) 
119 
79.01  
(4.1) 
Elevated 20     
54.3  
(101.0) 
168    
23.4 
 (2.3) 
2      
24.6 
(10.6) 
44      
20.8 
(3.2) 
16 
42.7 
(9.7) 
107 
26.2  
(2.6) 
7 
70.4  
(9.7) 
33 
21.0  
(4.1) 
HDL  
 
 
0.0722 
 
  
 
 
0.0194 
  
 
 
0.7747 
  
 
 
0.0229 
Low 27    
56.3  
(7.9) 
438   70.57 
(2.91) 
9        42.07 
(11.93) 
150                 
72.5  
(4.4) 
26 
59.3  
(9.1) 
260 
61.95 (3.28) 
11 
79.92 
(4.69) 
107 
66.93 (3.73) 
Elevated 18     
43.7  
(7.9) 
137    
29.4 
(2.9) 
5      
57.9  
(11.9) 
55             
27.5  
(4.4) 
13 
40.7  
(9.1) 
111 
38.1  
(3.3) 
5 
20.08 
(4.69) 
45 
33.07 (3.73) 
Triglycerides  
 
 
0.2381 
  
 
 
0.0193 
  
 
 
<0.0001 
  
 
 
0.4866 
Low 20     
68.5  
(7.6) 
427    
77.8  
(1.9) 
10              
70.3  
(10.6) 
185                  
91.0 
 (2.5) 
16 
39.3  
(6.9) 
271 
80.7 
(2.3) 
8 
75.1  
(5.8) 
121 
80.0 
 (4.3) 
Elevated 25     
31.5 
(7.6) 
148     
22.2  
(1.9) 
4                           
29.7  
(10.6) 
20                     
9.0 
(2.5) 
23 
60.7  
(6.9) 
100 
19.3 
(2.3) 
8 
24.9  
(5.8) 
31 
20.0  
(4.3) 
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Table 7 shows results of the logistic regression analysis. Among the general sample, there 
was no significant difference in the odds of being diagnosed with GDM between individuals with 
low cholesterol levels vs. individuals with high cholesterol levels in the crude (OR= 1.03, 95% 
CI= 0.59-1.79) and adjusted model (OR= 0.74, OR= 0.40-1.38). Individuals with high LDL lev-
els were significantly more likely to be diagnosed with diabetes when compared with individuals 
with low LDL in both the crude (OR=3.47; 95% CI=1.90-6.33), and adjusted model (OR=2.82; 
95% CI=1.17-6.75). 
             There was no significant difference in the odds of being diagnosed with GDM between 
individuals with high HDL levels vs. individuals with low HDL levels in the crude model (OR=  
0.66, 95% CI= 0.40-1.10) and adjusted (OR= 0.71, 95% CI= 0.43-1.19). Individuals with high 
triglycerides levels were significantly more likely to be diagnosed with diabetes when compared 
with individuals with low triglycerides in both the crude (OR= 2.44, 95% CI= 1.36-4.38), and 
adjusted model (OR= 1.30, 95% CI= 0.56-3.01). 
          There was no significant difference in the odds of being diagnosed with GDM between 
individuals who are underweight versus individuals with normal weight in the crude model (OR=  
0.43, 95% CI= 0.13-1.43) and adjusted (OR= 0.43, 95% CI= 0.12-1.56). Individuals who are 
overweight/obese were significantly more likely to be diagnosed with diabetes when compared 
with individuals of normal weight in both the crude (OR= 3.13, 95% CI= 1.28-7.64), and adjust-
ed model (OR= 2.44, 95% CI= 1.02-5.86). 
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Table 7:  Associations between metabolic profile and diabetes diagnosis 
  
Variable OR1 (95% CI) OR2 (95% CI) 
 
Cholesterol (mg/dl) 
       Low Reference Reference 
       Elevated 1.0 (0.6-1.8) 0.7 (0.4-1.4) 
 
LDL (mg/dl) 
       Low Reference Reference 
       Elevated 3.5 (1.9-6.3) 2.8 (1.2-6.8) 
 
HDL (mg/dl) 
       Low 0.7 (0.4-1.1) 0.7 (0.4-1.2) 
       Elevated Reference Reference 
 
Triglyceride (mg/dl) 
       Low Reference Reference 
       Elevated 2.4 (1.4-4.4) 1.3 (0.6-3.0) 
 
BMI (kg/m2) 
       Underweight 0.4 (0.1-1.4) 0.4 (0.12-1.6) 
       Normal Reference Reference 
       Overweight 3.13 (1.3-7.6) 2.4 (1.0-5.9) 
OR 1= Crude odds ratio; 
OR2= Adjusted odds ratio (adjusted for the effect of age, BMI, LDL, HDL, and triglyceride levels) 
 
            Tables 8 show the association between diabetes diagnosis and metabolic variables strati-
fied by race/ethnicity. Among non-Hispanic pregnant White women, individuals with elevated 
LDL levels, and who were overweight/obese were significantly more likely to be diagnosed with 
diabetes when compared to those with low LDL levels and normal weight respectively. For in-
stance, non-Hispanic white women with elevated LDL levels were nearly 4 times more likely to 
be diagnosed with diabetes when compared to those with low LDL levels in both the crude and 
adjusted models.  No other significant associations were observed within this group. 
Among non-Hispanic pregnant Black women, individuals with elevated triglycerides and 
who were underweight, or overweight/obese were significantly more likely to be diagnosed with 
diabetes when compared to those with low triglyceride levels, and who were normal weight re-
spectively. For instance, individuals with elevated triglyceride were significantly more likely to 
be diagnosed with diabetes in both the crude (OR=4.27; CI=1.4 – 13.4) and adjusted (adjusted 
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OR=5.10; CI=1.3 – 20.7) models. Also, women who were underweight were at least 5 times 
more likely to be diagnosed with diabetes when compared to those who were normal weight. 
           Among pregnant Mexican-American women, individuals with elevated triglyceride levels 
were significantly more likely to be diagnosed with diabetes when compared to those with low 
triglyceride levels in both the crude (OR= 6.5; 95% CI=3.4 – 12.4) and adjusted (OR=7.9; 95% 
CI=2.7 – 22.9) models. Similarly those who were overweight were significantly more likely to 
be diagnosed with diabetes when compared those who were normal weight in both the crude 
(OR= 7.9; 95% CI=5.2 – 12.1) and adjusted (OR= 5.5; 95% CI=3.2 – 9.5).   
        Among pregnant women from ‘Other’ race ethnicities, individuals with elevated LDL were 
significantly more likely to be diagnosed with diabetes in both the crude (OR=8.94 95% CI= 3.0 
– 27.0) and adjusted (OR=19.4; 95% CI=3.6 – 10.3.9). Also, individuals with low LDL levels 
were significantly more likely to be diagnosed with diabetes in the crude model (OR=1.97 95% 
CI= 1.0 – 3.4) but not in the adjusted model.  
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Table 8: Stratification of the association between diabetes diagnosis and metabolic variables into race/ethnicity.  
 
 Non-Hispanic Whites Non-Hispanic Blacks Mexican-Americans “Other” Races 
Variable OR1 
(95% CI) 
OR2 
(95% CI) 
OR1 
(95% CI) 
OR2 
(95% CI) 
OR1 
(95% CI) 
OR2 
(95% CI) 
OR1 
(95% CI) 
OR2  
(95%CI) 
Total Cholesterol 
Low Ref Ref Ref Ref Ref Ref Ref Ref 
Elevated 1.2 
(0.6-2.7) 
1.2 
(0.6-2.66) 
0.6 
(0.1-1.2) 
0.6 
(0.3-1.3) 
0.7 
(0.3-1.5) 
0.2 
(0.1-0.4) 
1.5 
(0.5-4.1) 
1.6 
(0.4-5.9) 
LDL 
Low Ref Ref Ref Ref Ref Ref Ref Ref 
Elevated 3.9  
(1.6-9.2) 
4.4 
(1.7-11.5) 
1.24 
(0.4-4.0) 
0.88  
(0.30-2.6) 
2.10  
(0.9-5.1) 
0.88 
 (0.2-3.2) 
8.94  
(3.0-27.0) 
19.44 
 (3.6-103.9) 
HDL 
Low 0.5  
(0.2-1.0) 
0.6  
(0.3-1) 
0.3  
(0.1-0.3) 
0.9  
(0.3-2.6) 
0.9  
(0.4-1.9) 
2.0  
( 01.0-2.0) 
2.0  
(1.1-3.4) 
1.6  
(0.7-3.9) 
Elevated 3Ref Ref Ref Ref Ref Ref Ref Ref 
Triglycerides 
Low Ref Ref Ref Ref Ref Ref Ref Ref 
Elevated 1.6 
 (0.7-3.5) 
0.5  
(0.2-1.2) 
4.2 
(1.4-3.4) 
5.1  
(1.3-20.7) 
6.46  
(3.38-12.37) 
7.86  
(2.70-22.86) 
1.33 (0.61-2.91) 0.30 
(0.05-1.93) 
BMI 
Underweight 0.43  
(0.10-1.9) 
0.3  
(0.08-1.6) 
5.00  
(2.95-8.49) 
6.0 
(2.4-14.7) 
2.4  
(0.5-12.7) 
7.9  
(2.7-22.9) 
* * 
Normal Ref Ref Ref Ref Ref Ref Ref Ref 
Overweight 3.8  
(1.1-13.3) 
23.0  
(0.8-10.4) 
12.5  
(7.2-21.6) 
11.8 
(6.4-21.7) 
7.9  
(5.2-12.1) 
5.5 
(3.2-9.5) 
0.8  
(0.2-3.7) 
0.8 
(0.4-1.9) 
 
OR 1= Crude odds ratio;   OR2= Adjusted odds ratio (adjusted for the effect of age, BMI, LDL, HDL, and triglyceride levels) 
                                  *= numbers too low for analysis 
 
 
 
 42 
 
Chapter V 
 
Discussion 
 
This study sought to determine the association between metabolic profiles and pregnancy 
in American women diagnosed with diabetes mellitus. American diabetic pregnant women were 
stratified by race/ethnicity (non-Hispanic Whites, non-Hispanic Blacks, Mexican-Americans, 
and “Other races”) to determine the effect of the metabolic variables (total cholesterol, LDL, 
HDL, and triglycerides) on diabetes diagnosis. It examined the differences in the metabolic pro-
files of pregnant women with prediabetes and diabetes; differences in the metabolic profile of 
non-Hispanic Whites, non-Hispanic Blacks, and Mexican-Americans, and other races. This study 
shows strong association of metabolic profiles with the diagnosis of GDM. Among the NH- 
Whites, elevated LDL and increased BMI are significantly more associated with positive GDM 
diagnosis; in the NH-Black and Mexican-Americans populations, elevated triglycerides and in-
creased BMI are significantly more associated with GDM diagnosis. In the “Other” races, ele-
vated LDL is more significantly more associated with the diagnosis of GDM. This shows that the 
association between various metabolic conditions and GDM diagnosis vary according to 
race/ethnicity. Rosenberg et al (2005) indicated that gestational diabetes was increasing among 
non-White women; the prevalence of diabetes among American women continues to increase, 
with non-Hispanic Blacks and Hispanics more likely to be affected than non-Hispanic Whites 
(Rosenberg et al, 2005).  
This study used NHANES data from 1999-2010. It is a nationally representative sample 
of the civilian non-institutionalized population of the US. In their study, Ziaea et al, 2006 noted 
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that normal human pregnancy results in a physiologic hyperlipidemia involving a gestational rise 
in blood triglyceride and cholesterol levels (Ziaea et al, 2006). However, in GDM there are in-
creased levels of maternal total cholesterol, probably related to alterations in the expression of 
proteins involved in lipid and cholesterol homeostasis (Leiva et al, 2013). Subjects with high to-
tal cholesterol had higher preeclampsia rate: RR of 1.39 (95% CI, 1.04–1.75), and that higher 
levels of triglycerides are independently and significantly associated with an increased risk for 
adverse pregnancy outcomes (Wiznitzer et al, 2009). This study shows a statistically significant 
difference (p<0.0001) in the mean levels of total cholesterol, LDL, HDL, and triglycerides be-
tween gestational diabetic women and non-diabetic pregnant women. In a comparative study, 
Khan et al, 2013 reported mean total cholesterol and mean triglyceride significantly higher at 
P<0.05 in GDM women as compared to non-diabetic pregnant women; their LDL cholesterol 
and HDL cholesterol levels in GDM women were non-significantly higher than in non-diabetic 
women (Khan, et al, 2013). They found that total cholesterol was 205.81 ± 19.09 mg/dL in GDM 
women, compared to 194.7 ± 23.7 mg/dL in non-diabetic pregnant women; triglycerides in GDM 
women was 189.6 ± 20.0 mg/dL in GDM women compared to 169 ± 22.3 mg/dL in non-diabetic 
pregnant women. In Table 4, the mean total cholesterol in GDM women is 210 ± 53.2 mg/dL 
compared to 221.4 ± 50.3 mg/dL in non-diabetic pregnant women; mean triglyceride is 190.4 ± 
102.2 mg/dL in GDM women compared to 178.4 ± 86.6 mg/dL in non-diabetic pregnant women. 
Obesity is a significant risk factor for GDM across all racial/ethnic groups (Golden, S.H. 
et al, 2012). This statement supports my findings. My study shows significant association of 
BMI with GDM diagnosis (p<0.0001) among all racial/ethnic groups (Table 6), indicating in-
creased risk of GDM with increasing BMI among races. This study is also supported by a previ-
ous study by Hedderson et al (2012). They found that the age-adjusted prevalence of GDM 
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among all racial/ethnic groups increased with increasing BMI. Across the racial/ethnic groups 
(Tables 6), my study shows a statistically significant (P<0.0001) relationship between obesity 
and diabetes diagnosis among pregnant women. Increasing BMI within the general population 
contributes not only to greater numbers of diabetic individuals, but also to a greater proportion of 
diabetic individuals who are extremely obese and, thus, to a greater proportion who are at risk of 
adverse outcomes (Leibson et al, 2001). 
Socioeconomic status is also associated with increase in GDM. In my study, GDM was 
diagnosed more in women with high school education or less (p=0.0294) as compared to those 
with at least college education (Table 5). Nearly 36% of women with less than high school edu-
cation were diagnosed with diabetes compared to just about 24% of those with high school edu-
cation. Golden et al report that women with less than high school education had 70% greater 
odds of having GDM than women with at least high school education; they also reported a 7% 
annual increase in GDM among women with a high school education compared with a 4% annu-
al increase among those with a college education (Golden et al, 2012). 
Among the non-Hispanic Blacks and “Other races”, my study show significant associa-
tion of lower education and being diagnosed with diabetes: for non-Hispanic Blacks P=0.0246, 
and for “Other races” P=0.0173. A study by Hedderson et al showed that Asian women were 
more educated and less likely to be overweight or obese compared to women from other ra-
cial/ethnic groups (Hedderson  et al, 2012). The number of respondents reporting income in my 
study was too low to run an analysis. But a study by Golden et al showed that being below the 
poverty limit also increased the odds of being diagnosed with GDM (Golden et al, 2012). 
 
 
 45 
 
Weakness/Limitations 
This is a cross-sectional study that uses secondary data from NHANES 1999-2010. 
Cross-sectional study does not have cause/effect relationship because it takes only a snap-shot at 
a point in time of the independent and outcome variables. Responses to questionnaires in  
NHANES 1999-2010 are self-reported. Therefore, the possibility of self-reporting biases cannot 
be ruled out. In addition, some of the variables received low responses. As a result, the low num-
bers are too small to be analyzed.  
 
Clinical Relevance 
Obesity and race/ethnicity are established risk factors GDM. In addition to these, high 
levels of cholesterol and triglycerides may be contributing factors for the development of GDM 
(Khan et al, 2013). GDM alters the expression of placental genes related to markers and media-
tors of inflammation and leads to impaired fetal growth and programming, which causes several 
metabolic diseases; it can accelerate the development of cardiovascular disease (CVD) in adult 
life (Sisino et al, 2013). Women with GDM are at high risk of recurrence of gestational diabetes 
and of developing type 2 DM in the future (Lawrence et al, 2008). The risks of developing dia-
betes and metabolic syndrome are increased in the decade after delivery, while the newborn in-
fants are at increased risk of developing obesity and diabetes in adolescence and adulthood (Fer-
rara, 2007). GDM plays a crucial role in the prevalence of obesity and diabetes. Other complica-
tions of GDM include macrosomia, spontaneous abortion, birth defects, cesarean section deliv-
ery, transient newborn hypoglycemia, and hypocalcmia.  
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Recommendations 
Based on the results of my study, the medical management of pregnant women with vari-
ous metabolic conditions may have to be modified dependent on the race/ethnicity of the indi-
vidual. Even though recommendations have already been put forward for the screening of meta-
bolic conditions during pregnancy, more particular attention should be paid to metabolic factors 
that shows significant factor according to race/ethnicity. Screening, including cholesterol and 
lipoprotein monitoring, should begin early in pregnancy and continued through postpartum.  
Since education is an important factor in diabetes prevention, women especially non-
Hispanic Blacks and Mexican-Americans, of childbearing age should be educated on the preva-
lence of diabetes, diabetes control, and the complications of diabetes. Lifestyle modification, in-
cluding weight loss, exercise, and healthy diet, should also be stressed, as obesity is one of the 
greatest contributors of diabetes. The information obtained from this cross-sectional study does 
not show a causal relationship. Future more rigorous studies should be conducted to determine if 
these findings can be replicated. Future investigations is also suggested to determine the associa-
tion between underweight and GDM among the NH-black women.is  
Conclusion 
With the exception of non-Hispanic Whites, pregnant American women with higher lev-
els of cholesterols, high triglycerides, increased body mass index (25 kg/m2 or greater), and less 
than high school education were found to be at greater risks of diabetes. The result of this analy-
sis suggests that healthcare professionals should be more aggressive in controlling these metabol-
ic abnormalities in pregnant women. Early intervention prior to pregnancies may help to onset of 
prediabetes/diabetes. Empowerment of pregnant women in the management of their diabetes 
may also be critical in averting the detrimental effect of these metabolic abnormalities. 
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Thank you, O Lord, My God. I have called on you and you have answered me. To you 
alone be all the glory! 
 
 
